Efficacy of neutral electrolyzed water vs. common topical antiseptics in the healing of full‑thickness burn: Preclinical trial in a mouse model.

burn injury histological characteristic inflammation neutral electrolyzed water preclinical trial wound healing

Journal

Biomedical reports
ISSN: 2049-9442
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227

Informations de publication

Date de publication:
Dec 2024
Historique:
received: 02 07 2024
accepted: 06 09 2024
medline: 31 10 2024
pubmed: 31 10 2024
entrez: 31 10 2024
Statut: epublish

Résumé

Burn injuries impose challenges such as infection risk, pain management, fluid loss, electrolyte imbalance and psychological and emotional impact, on healthcare professionals, requiring effective treatments to enhance wound healing. The present study evaluated the efficacy superoxidized electrolyzed solution (SES), with low (SES-low) or high (SES-high) concentrations of active species, alone or in combination with a formulation in gel (G), in comparison with commonly prescribed treatments for burn injury, including nitrofurazone (NF) and silver sulfadiazine (S); normal saline was used as placebo (PI). A scald burn model was established in BALB/c mice. Measurements of the burned area and histological parameters such as inflammatory infiltration state, epithelial regeneration and collagen fibers were evaluated on days 3, 6, 9, 18 and 32 to assess healing score and status. All treatments achieved wound closure at day 32; histopathological parameters indicated that SES-low and SES-low + G performed better than the Pl and S groups (P<0.05). All treatments showed a lower count of inflammatory cells compared with S (P<0.05); for collagen deposition and orientation, SES-low + G showed a more uniform horizontal orientation compared with Pl, SES-high + G, NF and S groups (P<0.05). SES-Low was the most effective substance to induce favorable and organized healing, while S was the worst, inducing disorganized closure of the wound due to a pro-inflammatory effect.

Identifiants

pubmed: 39479362
doi: 10.3892/br.2024.1877
pii: BR-21-6-01877
pmc: PMC11522847
doi:

Types de publication

Journal Article

Langues

eng

Pagination

189

Informations de copyright

Copyright: © 2024 Delgado‑Enciso et al.

Déclaration de conflit d'intérêts

BPM and ACL are employees at Esteripharma but did not participate in the decision to publish the results of the study, nor in its development or data collection. The rest of the authors declare that they have no competing interests.

Auteurs

Ivan Delgado-Enciso (I)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
Department of Research, State Cancerology Institute of Colima, Health Services of The Mexican Social Security Institute for Welfare (IMSS-BIENESTAR Colima), Colima 28085, Mexico.
Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA.

Nomely S Aurelien-Cabezas (NS)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Carmen Meza-Robles (C)

Department of Research, State Cancerology Institute of Colima, Health Services of The Mexican Social Security Institute for Welfare (IMSS-BIENESTAR Colima), Colima 28085, Mexico.

Mireya Walle-Guillen (M)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Gustavo A Hernandez-Fuentes (GA)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Ariana Cabrera-Licona (A)

Department of Research, Esteripharma SA de CV, Atlacomulco 50450, Mexico.

Alejandra E Hernandez-Rangel (AE)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Marina Delgado-Machuca (M)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Alejandrina Rodriguez-Hernandez (A)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Oscar F Beas-Guzman (OF)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Citlaly B Cardenas-Aguilar (CB)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Iram P Rodriguez-Sanchez (IP)

Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo León, San Nicolás de los Garza 66455, Mexico.

Margarita L Martinez-Fierro (ML)

Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, México.

Daniel Chaviano-Conesa (D)

Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.

Brenda A Paz-Michel (BA)

Department of Research, Esteripharma SA de CV, Atlacomulco 50450, Mexico.

Classifications MeSH